Loading…
Enliven Therapeutics, Inc. is projected to rise to $72.92 by 2027, a +35% move from its current price of $53.95. ELVN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $52.62 | $53.99 | $55.39 | +0.07% |
| Aug 2 | $52.10 | $54.02 | $56.02 | +0.14% |
| Aug 3 | $51.71 | $54.06 | $56.52 | +0.21% |
| Aug 4 | $51.39 | $54.10 | $56.95 | +0.28% |
| Aug 5 | $51.12 | $54.14 | $57.34 | +0.35% |
| Aug 6 | $50.87 | $54.18 | $57.69 | +0.42% |
| Aug 7 | $50.65 | $54.21 | $58.03 | +0.49% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $50.65 | $54.21 | $58.03 | +0.49% |
| Week 2 | $49.49 | $54.48 | $59.97 | +0.98% |
| Week 3 | $48.66 | $54.74 | $61.58 | +1.47% |
| Week 4 | $48.02 | $55.01 | $63.02 | +1.96% |
| Week 5 | $47.48 | $55.28 | $64.35 | +2.46% |
| Week 6 | $47.03 | $55.55 | $65.61 | +2.96% |
| Week 7 | $46.63 | $55.82 | $66.81 | +3.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer.
Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
The company was founded in 2019 and is headquartered in Boulder, Colorado.
ELVN is currently trading at $54.33 with a market cap of $3.88B, and it holds a rank of 1561.
Listed in the Healthcare sector, Enliven Therapeutics operates as a clinical-stage biopharmaceutical company focused on cancer therapies.
The forecast provides an overall price outlook with notable upside over the longer term, including an average of $146.57 by 2030 and $1,018.60 by 2050, among other milestones.
In 2026 the forecast shows an average of $54.33 with a neutral sentiment; from 2027 onward the outlook is bullish.
A major floor 42.9% below — a decisive break under it would weaken the trend.
The nearest floor, 16.8% below — buyers have tended to step in here.
Price is pressing into resistance (0.7% away) — a breakout level to watch.
A major ceiling 12.2% above — clearing it would confirm fresh momentum.
Key ELVN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ELVN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $53.27 | Buy | $53.37 | Buy |
| MA 10 | $53.12 | Buy | $52.95 | Buy |
| MA 20 | $52.13 | Buy | $51.70 | Buy |
| MA 50 | $46.24 | Buy | $47.80 | Buy |
| MA 100 | $42.64 | Buy | $42.77 | Buy |
| MA 200 | $32.63 | Buy | $36.19 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.23 | Neutral |
| Stoch RSI (14) | 26.74 | Neutral |
| CCI (20) | 105.97 | Buy |
| Williams %R (14) | -10.95 | Info |
| MACD (12,26,9) | -0.24 | Sell |
| ROC (12) | 4.29 | Buy |
| Bollinger %B (20,2) | 0.85 | Neutral |
| Stochastic %K (14) | 89.05 | Sell |
| TRIX (15) | 0.67 | Buy |
| Awesome (5,34) | 3.39 | Buy |
| Ultimate (7,14,28) | 52.32 | Neutral |
| Momentum (10) | 3.09 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 53.50 | Buy |
| ADX (14) | 24.05 | Buy |
| ATR (14) | 1.11 | Info |
The near-term technical picture is bullish, with sentiment labeled as BULLISH.
The RSI(14) is 60, and the moving averages stand at SMA50 = $44.60 and SMA200 = $31.48.
Support is identified at $33.63 and resistance at $54.33, while the 30-day price range spans from $44.45 to $66.41.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.14 | $53.95 | $73.13 | 0% | Neutral | |
| $58.46 | $72.92 | $95.96 | +35% | Bullish | |
| $69.25 | $88.68 | $120.94 | +64% | Bullish | |
| $92.51 | $121.08 | $169.77 | +124% | Bullish | |
| $108.56 | $144.83 | $207.87 | +168% | Bullish | |
| $110.03 | $149.36 | $218.77 | +177% | Bullish | |
| $126.58 | $174.63 | $260.51 | +224% | Bullish | |
| $139.40 | $195.24 | $296.11 | +262% | Bullish | |
| $155.16 | $220.47 | $339.49 | +309% | Bullish | |
| $198.03 | $285.25 | $445.50 | +429% | Bullish | |
| $271.66 | $416.33 | $689.92 | +672% | Bullish | |
| $606.14 | $1,032.65 | $1,865.92 | +18.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $15.14 | $53.95 | $62.89 | +0.00% |
| August 2026 | $47.11 | $55.22 | $66.18 | +2.35% |
| September 2026 | $48.65 | $57.48 | $69.77 | +4.09% |
| October 2026 | $48.37 | $57.51 | $70.50 | +0.05% |
| November 2026 | $47.79 | $57.11 | $70.58 | -0.70% |
| December 2026 | $48.93 | $58.75 | $73.13 | +2.87% |
Click any year to see its month-by-month ELVN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ELVN is projected to trade between $15.14 and $73.13, averaging $53.95 — a potential gain of 0% from today's $53.95. Price action looks broadly range-bound.
Enliven Therapeutics, Inc.'s 2027 outlook centres on $72.92, within a $58.46 to $95.96 range. That is up +35% on the projected 2026 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, ELVN could reach as high as $120.94, with a base case around $88.68 and support toward $69.25 — roughly +64% from $53.95. Momentum favours further upside here.
Expect ELVN to range from $92.51 to $169.77 through 2029. The $121.08 average target implies a +124% move from current prices. That is up +37% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The ELVN price prediction for 2030 points to an average of $144.83 (low $108.56, high $207.87) — a potential gain of +168% on today's $53.95. Momentum favours further upside here.
In 2031, ELVN is projected to trade between $110.03 and $218.77, averaging $149.36 — a potential gain of +177% from today's $53.95. That is up +3% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Enliven Therapeutics, Inc.'s 2032 outlook centres on $174.63, within a $126.58 to $260.51 range. That is up +17% on the projected 2031 average. That marks a +224% change versus current levels. Momentum favours further upside here.
By 2033, ELVN could reach as high as $296.11, with a base case around $195.24 and support toward $139.40 — roughly +262% from $53.95. Buyers look set to stay in control over this stretch.
Expect ELVN to range from $155.16 to $339.49 through 2034. The $220.47 average target implies a +309% move from current prices. That is up +13% on the projected 2033 average. Momentum favours further upside here.
The ELVN price prediction for 2035 points to an average of $285.25 (low $198.03, high $445.50) — a potential gain of +429% on today's $53.95. Buyers look set to stay in control over this stretch.
In 2040, ELVN is projected to trade between $271.66 and $689.92, averaging $416.33 — a potential gain of +672% from today's $53.95. That is up +46% on the projected 2035 average. Momentum favours further upside here.
Enliven Therapeutics, Inc.'s 2050 outlook centres on $1,032.65, within a $606.14 to $1,865.92 range. That is up +148% on the projected 2040 average. That marks a +18.1x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ELVN today (≈ 18.535681 ELVN) could be worth
$19,140.94
+$18,140.94 (+1814%) by 2050 · US Dollar
Based on the average projected ELVN price of $1,032.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ELVNwould be worth at today's price.
$1,000 invested in ELVN on Jul 30, 2025 (≈ 51.759835 ELVN) would be worth
$2,792.44
+$1,792.44 (+179.2%) today · 2.79× · US Dollar
Based on a ELVN entry price of $19.32 vs. today's $53.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $52.81 | $1,021.59 | +2.2% |
| 1 month ago | $50.75 | $1,063.05 | +6.3% |
| 3 months ago | $41.7 | $1,293.76 | +29.4% |
| 6 months ago | $26.45 | $2,039.7 | +104.0% |
| 1 year ago | $19.32 | $2,792.44 | +179.2% |
| All time (5.0y) ago | $22.08 | $2,443.39 | +144.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ELVN forecast.
Our base-case forecast reaches $110.00 around 2029.
Implied market cap at $110.00: $7.86B
The multi-year forecast shows bullish sentiment across the majority of years, with 2026 marked as neutral and subsequent years highlighted as bullish.
For 2030, the forecast shows an average price of $146.57 with a 169.8% ROI, indicating strong upside potential; the 2030 min and max are $106.53 and $217.98 respectively.
For 2040, the forecast shows an average price of $406.23 with a 647.7% ROI, and a min/max of $248.58 and $710.86.
For 2050, the forecast shows an average price of $1,018.60 with a 1,774.8% ROI, and a min/max of $544.23 and $1,963.17. These figures illustrate substantial long-run upside if the projected path holds, but they are estimates, not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $146.57, with a min of $106.53 and a max of $217.98, and a ROI of 169.8%; sentiment is BULLISH.
The current price is $54.33 and the market cap is $3.88B.
Yes. From 2027 onward the forecast is BULLISH, with 2027 avg $72.50, 2028 $89.61, 2029 $124.82, 2030 $146.57, 2031 $148.32, 2032 $174.96, 2033 $191.82, 2034 $216.70, 2035 $288.78, 2040 $406.23, and 2050 $1,018.60.
The 30-day range is $44.45 to $66.41.
The 2050 forecast shows an average of $1,018.60, with a min of $544.23 and a max of $1,963.17, and a ROI of 1774.8%; sentiment is BULLISH.
Enliven Therapeutics, Inc. Community Discussion
0Share your Enliven Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.